Authors : Minocha Dr. Pramod Kumar; Kothwala Dr. Deveshkumar; Pandya Kamna; Mistry Saurabh Rana Nirav; Sharma Rahul

Volume/Issue : Volume 9 - 2024, Issue 11 - November

Google Scholar : https://tinyurl.com/5fb7n244

Scribd : https://tinyurl.com/4ryz8dh4

DOI : https://doi.org/10.38124/ijisrt/IJISRT24NOV812

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : This study assessed the safety and performance of a patent ductus arteriosus (PDA) occluder using a porcine carotid artery model involving three male pigs. Each pig underwent a thorough physical examination and met the criteria for stable health and body weight. On day 0, the occluder was implanted under proper analgesia and anesthesia, with heparin used to prevent clot formation. The deployment process was meticulously evaluated through angiography and Quantitative Vascular Analysis (QVA) before and after implantation. Arteries were harvested at 90, 180, and 365 days for histopathological analysis. The occluder fulfilled all acceptance criteria, demonstrating successful deployment, trackability, and no cranial artery flow above the device. Gross necropsy showed a bulged carotid artery, suggesting a reaction to the device, while histopathological evaluations showed good endothelialization at all time points. The occluder was well-visualized during imaging, deployed easily, and could be withdrawn without issue. It effectively occluded the artery at all follow-ups without migrating from the target site. All animals survived the procedure and post- procedural period with the device intact. These results suggest that the PDA occluder is safe and effective in this model, showing promise for future human clinical applications, though further studies are needed to confirm long-term safety and efficacy.

Keywords : Patent Ductus Arteriosus (PDA) Occluder Device, Porcine Model, Safety Evaluation, Performance Assessment, Radiography And Angiographic Findings, Histopathological Findings.

References :

1. Dr. Minocha et al (2024). In-Vitro Assessment of Atrial Septal Defect Occluder Deployment: A Crucial Step in Occluding Atrial Septal Defects and Restoring Cardiac Function. International Journal of Innovative Science and Research Technology (IJISRT), Volume 9, Issue 6: 460-465.
2. Organization for Economic Co-operation and Development - Principles of GLP and Compliance Monitoring (as revised in 1997) ENV/MC/CHEM (98) 17.
3. Guidance Document on the Recognition, Assessment and Use of Clinical signs as humane endpoints for Experimental Animals used in Safety Evaluation. ENV/JM/MONO (2000)7. OECD, December, 2000.
4. Compendium of CPCSEA 2018; Guidelines for Laboratory Animal Facility 2015; 7: 61 – 96.
5. Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources. Commission on Life Sciences. National Research Council. National Academy Press. Washington, D.C. 1996.
6. Implants for surgery – Active implantable medical devices – Part 5: Circulatory support devices. (ISO 14708-5:2020).
7. CFR - Code of Federal Regulations Title 21- Part58: Good Laboratory Practice for Nonclinical Laboratory Studies (21 CFR 58) 2019.
8. Kornowskiet al (1998). In-Device Restenosis: Contributions of Inflammatory Responses and Arterial Injury to Neointimal Hyperplasia. J Am Coll Cardiol. 1: 224-230.
9. Schwartz et al (1992). Restenosis and the Proportional Neointimal Response to Coronary Artery Injury: Results in a Porcine Model JACC 19-2: 267-74.
10. Yazdani et al (2014). Vascular, Downstream, and Pharmacokinetic Responses to Treatment with a Low Dose Drug-Coated Balloon in a Swine Femoral Artery Model. Catheterization and Cardiovascular Interventions. 83 (1): 132-140.